Abstract
Brain metastases (BM) from solid tumors are increasing in incidence due to an early use of MRI for diagnosis and improvement of outcome of some molecular subgroups following targeted agents and immunotherapy. Surgical resection is a treatment of choice for solitary brain metastases in an accessible location and with a diameter ≥ 3 cm. Stereotactic radiosurgery may be indicated for single or multiple brain metastases, while whole-brain radiotherapy is reversed for palliation of symptoms only. EGFR or ALK inhibitors have allowed in BM from NSCLC a prolongation of median survival up to 3–4 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
